Core Viewpoint - Falcon Oil & Gas Ltd has announced a significant achievement in the Beetaloo Sub-basin, with the Shenandoah S2-2H ST1 well recording an average 30-day initial production (IP30) flow rate of 7.2 million cubic feet per day (MMcf/d), marking the highest IP30 result in the region to date [2][5]. Development Activity - The IP30 flow rate of 7.2 MMcf/d exceeds Falcon's pre-drill commercial threshold of 3 MMcf/d per 1,000 metres, indicating strong resource potential in the Beetaloo Sub-basin [5]. - The normalized flow rate of 13.2 MMcf/d over an extrapolated 10,000-foot horizontal section aligns with the average of over 11,000 wells in the Marcellus Shale dry gas area [6]. - The exit rate trajectory shows a steady decline at 6.7 MMcf/d, with a flowing wellhead pressure of approximately 910 psi, consistent with previous wells in the area [6]. - Falcon plans to complete and test the SS-4H well by the end of 2025, with a drilling campaign for three additional wells set to commence in July 2025 [6]. - The five wells on the SS2 pad are expected to be tied into the Sturt Plateau Compression Facility under a 40 MMcf/d take-or-pay Gas Sales Agreement with the Northern Territory Government, with production anticipated to start in mid-2026 [6].

Disclosure of trading in own shares occurred from June 9 to June 13, 2025 Saint-Cloud, June 16, 2025 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from June 9 to June 13, 2025 under the buyback program authorized by the 24th resolution of the General Shareholders' Meeting of May 22, 2025 and announced on March 6, 2025: Aggregated presentation: Issuer nameIssuer code(LEI) Transaction dateISIN CodeDaily ...

DIVERSIFIED ENERGY COMPANY PLC(the “Company") Q4 2024 Dividend Exchange Rate BIRMINGHAM, Ala. , June 16, 2025 (GLOBE NEWSWIRE) -- Diversified Energy Company PLC (LSE:DEC, NYSE:DEC) announced on April 9, 2025 a dividend in respect of the fourth quarter ended December 31, 2024 in the amount of 29 cents per share (the “Q4 2024 Dividend”.) The Company will pay the Q4 2024 Dividend on June 30, 2025 to those shareholders on the register on May 30, 2025. The Company announces that shareholders who have elected ...

Company announcement no. 34 / 2025Schindellegi, Switzerland – 16 June 2025 Trifork Group: Weekly report on share buyback On 28 February 2025, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 4 March 2025 up to and including no later than 30 June 2025. For details, please see company announcement no ...

Core Points - Jyske Bank has initiated a share repurchase program that will run from February 26, 2025, to January 30, 2026, with a total value of up to DKK 2.25 billion [1] - The program is structured in compliance with the EU Market Abuse Regulation and Safe Harbour Rules [1] Summary of Transactions - As of the latest announcement, Jyske Bank has repurchased a total of 1,025,529 shares at an average price of DKK 541.18, amounting to a total transaction value of DKK 554,995,995 [2] - The accumulated shares prior to the latest transactions were 982,403 shares at an average price of DKK 537.23, totaling DKK 527,780,007 [2] - The share repurchase program has resulted in Jyske Bank owning 1.67% of its share capital [2]

Core Viewpoint - WISeKey International Holding Ltd has appointed Rolf Gobet to its Strategic Advisory Committee, enhancing its leadership in cybersecurity, blockchain, and IoT sectors [1][6]. Company Overview - WISeKey is a global leader in cybersecurity, digital identity, and IoT solutions, operating as a Swiss-based holding company with several operational subsidiaries [6][8]. - The company has over 1.6 billion microchips deployed across various IoT sectors, playing a vital role in securing the Internet of Everything [7]. Rolf Gobet's Experience - Rolf Gobet brings over three decades of experience in managing complex public-private projects, including leading the implementation of the world's first internet voting solution in collaboration with WISeKey [3][4]. - He was instrumental in developing TOSA, the world's first fully electric bus system that charges on the go, showcasing his ability to unite stakeholders from government, industry, and academia [4][5]. - Gobet has directed the Office for the Promotion of Industries and Technologies (OPI) for over 10 years, supporting the economic development of various companies [5]. Strategic Importance - Carlos Moreira, Founder and CEO of WISeKey, emphasized that Gobet's pioneering achievements and vision for sustainable innovation make him a valuable asset to the company's global mission [6].

Core Insights - Roche has decided to advance the Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, for early-stage Parkinson's disease based on encouraging data from Phase IIb PADOVA and ongoing open-label extensions [1][2] Company Overview - Roche is committed to addressing the substantial need for new treatment options in Parkinson's disease, which currently affects over 10 million people globally [8][9] - The company has a licensing agreement with Prothena to develop monoclonal antibodies targeting aggregated alpha-synuclein, including prasinezumab [7] Clinical Development - The Phase IIb PADOVA study involved 586 participants with early-stage Parkinson's disease, showing potential clinical efficacy in delaying motor progression, although it missed statistical significance [5][6] - Positive trends were observed in reducing motor progression at 104 weeks, indicating a 30-40% relative reduction compared to placebo in both overall and levodopa-treated populations [5] - Ongoing studies, including PASADENA and PADOVA open-label extensions, are evaluating the long-term safety and efficacy of prasinezumab in over 750 participants [3][6] Mechanism of Action - Prasinezumab is designed to bind aggregated alpha-synuclein, potentially reducing neuronal toxicity and slowing disease progression by preventing further accumulation of this protein in the brain [4][9] Industry Context - Parkinson's disease is a chronic and progressive neurodegenerative disorder with no current therapies that can slow or halt its progression, highlighting the unmet medical need for disease-modifying treatments [9][10]

Group 1: Company Overview - Constellium SE (NYSE: CSTM) is a global leader in developing innovative, value-added aluminum products for various markets, including aerospace, packaging, and automotive [5] - The company generated $7.3 billion in revenue in 2024 [5] Group 2: Innovations and Products - At the 55th Paris Air Show, Constellium will showcase its high-performance aluminum products, including Airware, an aluminum-lithium solution designed for aircraft and spacecraft applications [2] - Airware provides superior strength-to-weight ratios, reduced material density, and excellent fatigue and corrosion resistance, making it suitable for more efficient, lower-emission aircraft [2] Group 3: Sustainability Initiatives - Constellium will unveil the first aluminum ingot fully manufactured at lab scale from end-of-life aircraft, utilizing a recycling and remelting process that meets new aircraft production standards [3] - This initiative is a collaboration between Constellium and TARMAC Aerosave, supported by Airbus, representing a significant advancement toward a circular economy in aerospace [3] Group 4: Future Projects - The exhibit will also highlight the company's progress on the Wing of the Future project, aimed at developing next-generation wing technologies for lighter, more fuel-efficient aircraft [4] - The role of aluminum in sustainable aviation will be explored, with additional resources available for further insights [4]

Core Insights - Ascentage Pharma announced results from 13 studies of its key assets, including olverembatinib and APG-5918, at the 2025 European Hematology Association Annual Congress, highlighting their potential in treating unmet medical needs in cancers [1][2][3] Group 1: Olverembatinib - Olverembatinib, a third-generation tyrosine kinase inhibitor, showed significant clinical benefits in treating Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), with high complete remission (CR) and complete molecular response (CMR) rates [2] - In a study combining olverembatinib with blinatumomab, all patients achieved CR after one treatment cycle, with an overall survival (OS) rate of 100% and an event-free survival (EFS) rate of 91.6% at 18 months [6] - The combination of olverembatinib with the VP regimen resulted in a 100% overall response rate (ORR) and a 97.3% CR rate, indicating its effectiveness as a first-line therapy for adult patients with Ph+ ALL [11] Group 2: APG-5918 - APG-5918, an investigational EED inhibitor, demonstrated potent antitumor activity in preclinical studies for T-cell lymphoma, supporting its further clinical development [3][18] - The combination of APG-5918 with histone deacetylase inhibitor tucidinostat showed enhanced antitumor effects, indicating its potential as a therapeutic option [18] Group 3: Company Overview - Ascentage Pharma is focused on addressing unmet medical needs in cancers and has developed a pipeline of innovative drug candidates, including olverembatinib and APG-5918 [13] - The company is conducting global registrational Phase III trials for olverembatinib in various indications, including newly diagnosed Ph+ ALL and GIST patients [14]

Core Viewpoint - Abaxx Technologies Inc. has launched its physically-deliverable Gold Singapore Futures, which began active trading on June 12, 2025, providing a new tool for price discovery and hedging in the Asian market [1][3]. Company Overview - Abaxx Technologies is a financial software and market infrastructure company, and the majority shareholder of Abaxx Singapore Pte Ltd., which owns the Abaxx Commodity Exchange and Clearinghouse [1][7]. - The company aims to create Smarter Markets by developing better tools and technology to address significant societal challenges, including the energy transition [6]. Product Details - The Gold Singapore Futures contract is a USD-denominated, kilobar-sized product designed for the regional physical bullion trade, deliverable into approved vaults in Singapore [2][3]. - This contract is tailored for refiners, industrial consumers, banks, and physical traders in Asia, addressing the growing demand for regional price transparency [3][5]. Market Participation - The initial trading sessions of the Gold Singapore Futures saw participation from eight market makers, including firms from Singapore, Hong Kong, London, and Thailand, with expectations for more participants in the future [4]. - KGI Securities Singapore expressed enthusiasm for the new offering, highlighting its relevance to the Asian market and commitment to providing comprehensive solutions in commodities [5]. Trading Specifications - The Abaxx Gold Singapore Futures contract is available for trading 14 hours per day, Monday through Friday, facilitating access for market participants [5].